Erratum to Risk factors for fluconazole-resistant invasive candidiasis in intensive care unit patients: An analysis from the China Survey of Candidiasis study [Journal of Critical Care, 30, (2015), 862.e1-862.e5], DOI: 10.1016/j.jcrc.2015.04.002;Risk factors for fluconazole-resistant invasive candidiasis in intensive care unit patients: An analysis from the China Survey of Candidiasis study

Journal of Critical Care

Volumn 30, Issue 4, 2015, Pages 862.e1-862.e5

  Liao, Xuelian ^a   Qiu, Haibo ^b   Li, Ruoyu ^c   Guo, Fengmei ^b   Liu, Wei ^c   Kang, Mei ^a   Kang, Yan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Fluconazole resistance; Intensive care unit; Invasive Candida infection; Invasive candidiasis

Indexed keywords

FLUCONAZOLE; QUINOLONE DERIVATIVE; ANTIFUNGAL AGENT;

ADULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL THERAPY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CHEMOTHERAPY; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DISEASE CLASSIFICATION; DRUG EXPOSURE; FEMALE; FLUCONAZOLE RESISTANT INVASIVE CANDIDIASIS; FUNGAL COLONIZATION; FUNGUS ISOLATION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT PATIENT; INTRAABDOMINAL HYPERTENSION; INVASIVE CANDIDIASIS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MORTALITY; NONHUMAN; PATIENT; PATIENT CODING; PICHIA KUDRIAVZEVII; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION; AGED; CANDIDA; CANDIDIASIS, INVASIVE; CHINA; COHORT ANALYSIS; HETEROZYGOTE; HOSPITALIZATION; INTENSIVE CARE; INTENSIVE CARE UNIT; INTESTINAL PERFORATION; INTRA-ABDOMINAL HYPERTENSION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; QUESTIONNAIRE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, INVASIVE; CARRIER STATE; CHINA; COHORT STUDIES; CRITICAL CARE; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; INTESTINAL PERFORATION; INTRA-ABDOMINAL HYPERTENSION; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84930764187     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2015.07.011     Document Type: Erratum

References (19)

1. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
2. Vincent J.L., Rello J., Marshall J., Silva E., Anzueto A., Martin C.D., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
3. Kett D.H., Azoulay E., Echeverria P.M., Vincent J.L. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011, 39:665-670.
4. Guo F., Yang Y., Kang Y., Zang B., Cui W., Qin B., et al. Invasive candidiasis in intensive care units in China: a multicentre prospective observational study. J Antimicrob Chemother 2013, 68:1660-1668.
5. Puig-Asensio M., Peman J., Zaragoza R., Garnacho-Montero J., Martin-Mazuelos E., Cuenca-Estrella M., et al. Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med 2014, 42:1423-1432.
6. Leroy O., Gangneux J.P., Montravers P., Mira J.P., Gouin F., Sollet J.P., et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009, 37:1612-1618.
7. Leroy O., Mira J.P., Montravers P., Gangneux J.P., Lortholary O. Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care 2010, 14:R98.
8. Chi H.W., Yang Y.S., Shang S.T., Chen K.H., Yeh K.M., Chang F.Y., et al. Candida albicans versus non-albicans bloodstream infections: the comparison of risk factors and outcome. J Microbiol Immunol Infect 2011, 44:369-375.
9. Tapia G.G., Razonable R.R., Eckel-Passow J.E., Lahr B.D., Afessa B., Keegan M.T., et al. A scoring model of factors associated with Candida glabrata candidemia among critically ill patients. Mycoses 2012, 55:228-236.
10. Cisterna R., Tellería O., Hernaez S., Ezpeleta G. Impact of the new clinical breaking points proposed by the Clinical and Laboratory Standards Institute (CLSI) in the antifungal susceptibility profile of clinical strains isolated from invasive bloodstream Candida spp. infections in Spain. Clin Med Insights 2012, 4:19-27.
11. Orasch C., Marchetti O., Garbino J., Schrenzel J., Zimmerli S., Mühlethaler K., et al. The Fungal Infection Network of S. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect 2014, 20:698-705.
12. Lee I., Fishman N.O., Zaoutis T.E., Morales K.H., Weiner M.G., Synnestvedt M., et al. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med 2009, 169:379-383.
13. Maldonado N.A., Cano L.E., De Bedout C., Arbelaez C.A., Roncancio G., Tabares A.M., et al. Association of clinical and demographic factors in invasive candidiasis caused by fluconazole-resistant Candida species: a study in 15 hospitals, Medellin, Colombia 2010-2011. Diagn Microbiol Infect Dis 2014, 79:280-286.
14. Garnacho-Montero J., Diaz-Martin A., Garcia-Cabrera E., Ruiz Perez de Pipaon M., Hernandez-Caballero C., Aznar-Martin J., et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010, 54:3149-3154.
15. Slavin M.A., Sorrell T.C., Marriott D., Thursky K.A., Nguyen Q., Ellis D.H., et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010, 65:1042-1051.
16. Ben-Ami R., Olshtain-Pops K., Krieger M., Oren I., Bishara J., Dan M., et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother 2012, 56:2518-2523.
17. Ylipalosaari P., Ala-Kokko T.I., Karhu J., Koskela M., Laurila J., Ohtonen P., et al. Comparison of the epidemiology, risk factors, outcome and degree of organ failures of patients with candidemia acquired before or during ICU treatment. Crit Care 2012, 16:R62.
18. Pfaller M.A., Messer S.A., Woosley L.N., Jones R.N., Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013, 51:2571-2581.
19. Shah D.N., Yau R., Lasco T.M., Weston J., Salazar M., Palmer H.R., et al. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother 2012, 56:3239-3243.